Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 9/2019

Open Access 01-09-2019 | Atopic Dermatitis

Process utilities for topical treatment in atopic dermatitis

Authors: Jenny Retzler, Adam Smith, Matthew Reaney, Raj Rout, Richard Hudson

Published in: Quality of Life Research | Issue 9/2019

Login to get access

Abstract

Purpose

Management of atopic dermatitis (AD) typically requires application of topical treatments, often multiple times a day. The cosmetic properties and burdensome application of these treatments can be detrimental to quality of life (QoL). Patients who achieve good disease control through use of systemic therapies may reduce the frequency and amount of topical applications, improving QoL. This study aimed to quantify the utility and disutility for topical AD treatment processes.

Methods

Seven vignettes describing different skincare regimens for people with moderate-to-severe AD were developed with input from healthcare professionals. 484 respondents from the general population completed time trade-off items for each vignette. Utility values for each regimen, and disutilities associated with the impact of changes to skincare regimens, were calculated. Analysis of variance assessed differences between skincare regimens.

Results

As skincare regimens increased in intensity (0.7968 for the most intense; 0.9999 for the least), utility values decreased. There were no statistically significant differences between skincare regimens followed by patients with good disease control (0.9862 to 0.9999); however, when compared to those involving topical corticosteroids and emollient combinations (0.7968 to 0.8835), significant differences were observed (p < 0.001). The largest disutilities (0.1521 to 0.1705) were between skincare regimens describing the use of topical corticosteroids plus emollient and those followed by patients with good disease control.

Conclusions

The application of topical treatments has a detrimental effect on QoL, which increases with the duration and frequency of applications. Further research is needed to investigate how health and process utilities interact and both can be integrated into medical decision-making.
Appendix
Available only for authorised users
Literature
1.
Muto, T., Hsieh, S. D., Sakurai, Y., Yoshinaga, H., Suto, H., Okumura, K., et al. (2003). Prevalence of atopic dermatitis in Japanese adults. British Journal of Dermatology, 148(1), 117–121.CrossRefPubMed
2.
Barbarot, S., Auziere, S., Gadkari, A., Girolomoni, G., Puig, L., Simpson, E. L., et al. (2018). Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy, 73, 1284.CrossRefPubMed
3.
Zuberbier, T., Orlow, S. J., Paller, A. S., Taieb, A., Allen, R., Hernanz-Hermosa, J. M., et al. (2006). Patient perspectives on the management of atopic dermatitis. The Journal of Allergy and Clinical Immunology, 118(1), 226–232.CrossRefPubMed
4.
Drucker, A. M., Wang, A. R., Li, W. Q., Sevetson, E., Block, J. K., & Qureshi, A. A. (2017). The burden of atopic dermatitis: Summary of a report for the national eczema association. Journal of Investigative Dermatology, 137(1), 26–30.CrossRefPubMed
5.
Simpson, E. L., Bieber, T., Eckert, L., Wu, R., Ardeleanu, M., Graham, N. M., et al. (2016). Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. Journal of the American Academy of Dermatology, 74(3), 491–498.CrossRefPubMed
6.
Yu, S. H., & Silverberg, J. I. (2015). Association between atopic dermatitis and depression in US adults. The Journal of Investigative Dermatology, 135(12), 3183–3186.CrossRefPubMed
7.
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., et al. (2014). Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. Journal of the American Academy of Dermatology, 71(1), 116–132.CrossRefPubMedPubMedCentral
8.
9.
10.
Su, J., Kemp, A., Varigos, G., & Nolan, T. (1997). Atopic eczema: Its impact on the family and financial cost. Archives of Disease in Childhood, 76(2), 159–162.CrossRefPubMedPubMedCentral
11.
Carroll, C. L., Balkrishnan, R., Feldman, S. R., Fleischer, A. B., Jr., & Manuel, J. C. (2005). The burden of atopic dermatitis: Impact on the patient, family, and society. Pediatric Dermatology, 22(3), 192–199.CrossRefPubMed
12.
Stewart, K. D., Johnston, J. A., Matza, L. S., Curtis, S. E., Havel, H. A., Sweetana, S. A., et al. (2016). Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence, 10, 1385–1399.CrossRefPubMedPubMedCentral
13.
Florek, A. G., Wang, C. J., & Armstrong, A. W. (2018). Treatment preferences and treatment satisfaction among psoriasis patients: A systematic review. Archives of Dermatological Research, 310(4), 271–319.CrossRefPubMed
14.
Fouere, S., Adjadj, L., & Pawin, H. (2005). How patients experience psoriasis: Results from a European survey. Journal of the European Academy of Dermatology and Venereology, 19(Suppl 3), 2–6.CrossRefPubMed
15.
Schmitt, J., Wozel, G., Garzarolli, M., Viehweg, A., Bauer, M., & Leopold, K. (2014). Effectiveness of interdisciplinary vs. dermatological care of moderate-to-severe psoriasis: a pragmatic randomised controlled trial. Acta dermato-venereologica, 94(2), 192–197.CrossRefPubMed
16.
Eichenfield, L. F., Ahluwalia, J., Waldman, A., Borok, J., Udkoff, J., & Boguniewicz, M. (2017). Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. Journal of Allergology, 139(4S), S49–S57.
17.
18.
Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRefPubMed
19.
Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21(2), 271–292.CrossRefPubMed
20.
Drummond, M. F., O’Brien, B. J., Stoddart, G. L., & Torrance, G. W. (2000). Methods for the economic evaluation of health care programmes. New York, NY: Oxford University Press.
21.
Brennan, V. K., & Dixon, S. (2013). Incorporating process utility into quality adjusted life years: A systematic review of empirical studies. PharmacoEconomics, 31(8), 677–691.CrossRefPubMed
22.
23.
McGill, R., Tukey, J. W., & Larsen, W. A. (1978). Variations of box plots. American Statistician, 32(1), 12–16.
24.
Schofield. J., Grindlay. D. & Williams, G. 2009. Skin conditions in the UK: A health care needs assessment.
25.
National Institute for Health and Care Excellence. Dupilumab for treating moderate to severe atopic dermatitis after topical treatments [ID1048]. Single Technology Appraisal 534. Committee Papers. 2018
26.
Eckert, L., Gupta, S., Amand, C., Gadkari, A., Mahajan, P., & Gelfand, J. M. (2017). Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. Journal of the American Academy of Dermatology, 77(2), 274–279.CrossRefPubMed
27.
Schmitt, J., Meurer, M., Klon, M., & Frick, K. D. (2007). Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: A population-based study. British Journal of Dermatology, 158(2), 351–359.CrossRefPubMed
28.
29.
Sullivan, P. W. (2011). Are utilities bounded at 1.0? Implications for statistical analysis and scale development. Medical Decision Making, 31(6), 787–789.CrossRefPubMed
30.
Stiggelbout, A. M., & de Vogel-Voogt, E. (2008). Health state utilities: A framework for studying the gap between the imagined and the real. Value Health., 11(1), 76–87.CrossRefPubMed
31.
Krejci-Manwaring, J., McCarty, M. A., Camacho, F., Carroll, C. L., Johnson, K., Manuel, J., et al. (2006). Adherence with topical treatment is poor compared with adherence with oral agents: Implications for effective clinical use of topical agents. Journal of the American Academy of Dermatology, 54(5 Suppl), S235–S236.CrossRefPubMed
32.
Devaux, S., Castela, A., Archier, E., Gallini, A., Joly, P., Misery, L., et al. (2012). Adherence to topical treatment in psoriasis: A systematic literature review. Journal of the European Academy of Dermatology and Venereology, 26(Suppl 3), 61–67.CrossRefPubMed
33.
Attema, A. E., Edelaar-Peeters, Y., Versteegh, M. M., & Stolk, E. A. (2013). Time trade-off: One methodology, different methods. The European Journal of Health Economics, 14(S1), 53–64.CrossRefPubMedCentral
34.
Ternent, L., & Tsuchiya, A. (2013). A note on the expected biases in conventional iterative health state valuaion protocols. Medical Decision Making, 33(4), 544–546.CrossRefPubMed
Metadata
Title
Process utilities for topical treatment in atopic dermatitis
Authors
Jenny Retzler
Adam Smith
Matthew Reaney
Raj Rout
Richard Hudson
Publication date
01-09-2019
Publisher
Springer International Publishing
Published in
Quality of Life Research / Issue 9/2019
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-019-02174-0

Other articles of this Issue 9/2019

Quality of Life Research 9/2019 Go to the issue

OriginalPaper

Responsiveness of the EQ-5D-3L and EQ-5D-5L in patients following total hip or knee replacement

OriginalPaper

Posttraumatic stress and health-related quality of life in parents of children with cardiac rhythm devices

OriginalPaper

Psychometric properties and cross-language equivalence of the revised Bristol Rheumatoid Arthritis Fatigue and the Rheumatoid Arthritis Impact of Disease scales in rheumatoid arthritis

OriginalPaper

Association of the built environments and health-related quality of life in community-dwelling older adults: a cross-sectional study

OriginalPaper

Health-related quality of life in adult males with lower urinary tract symptoms

Commentary

Methods for questionnaire design: a taxonomy linking procedures to test goals